AMCF [Andatee China Marine Fuel Services] 8-K: EX-99.1 2 v175994_ex99-1.htm
[EX-99.1 2 v175994_ex99-1.htm] [Section 7 – Regulation FD Item 7.01 Regulation FD Disclosure http://www.andatee.com (d)]
NFEC [NF Energyvingrp] 8-K: (Original Filing)
[FORM 8-K CURRENT REPORTte of Report (Date of earliest event reported):February 24, 2010 NF ENERGYVINGRPORATION Delaware 000-50155 02-0563302 (State or Other Jurisdiction oforporation) (IRS Employer Identification No.) 21 - Jia Bei Si Dong Road, Tie Xi Qu Shenyang, P.R. China 110021 (Zipde) (8624) 2560-9750 (Former Name or Formerdress, if Changed Since Last Report)]
NFEC [NF Energyvingrp] 8-K: FORM 8-K CURRENT REPORTte of Report (Date of
[FORM 8-K CURRENT REPORTte of Report (Date of earliest event reported):February 24, 2010 NF ENERGYVINGRPORATION Delaware 000-50155 02-0563302 (State or Other Jurisdiction oforporation) (IRS Employer Identification No.) 21 - Jia Bei Si Dong Road, Tie Xi Qu Shenyang, P.R. China 110021 (Zipde) (8624) 2560-9750 (Former Name or Formerdress, if Changed Since Last Report)]
BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)
[Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of $69 to $71 million and Net Income $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with net income of $16.2 million to $17 million, excluding any non-cash charges. Management anticipates sales of its flagship product, Xin Aoxing, will represent approximately 68% to]
BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of
[Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of $69 to $71 million and Net Income $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with net income of $16.2 million to $17 million, excluding any non-cash charges. Management anticipates sales of its flagship product, Xin Aoxing, will represent approximately 68% to]
BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)
[Biostar Pharmaceuticals, Announces 2010 Guidance: Revenues of $69 to $71 million and Netome $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with netome of $16.2 million to $17 million, excluding any non-cash charges. Management anticipatesles of its flagship product, Xin Aoxing, will represent approximately 68%]
BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Announces 2010 Guidance: Revenues of $69
[Biostar Pharmaceuticals, Announces 2010 Guidance: Revenues of $69 to $71 million and Netome $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with netome of $16.2 million to $17 million, excluding any non-cash charges. Management anticipatesles of its flagship product, Xin Aoxing, will represent approximately 68%]
NFEC [NF Energy Saving] 8-K: (Original Filing)
[NF Energy Saving Corporation Issues Preliminary 2009 Results The Company Expects 28% Revenue Growth and 250% EPS Growth Year over Year SHENYANG, China, February 25, 2010 For the year ended December 31, 2009, the Company anticipates it will record revenues in the range of $20 to $21 million, which represents an approximate increase of 28% when compared to $15.83 of]
NFEC [NF Energy Saving] 8-K: NF Energy Saving Corporation Issues Preliminary 2009 Results
[NF Energy Saving Corporation Issues Preliminary 2009 Results The Company Expects 28% Revenue Growth and 250% EPS Growth Year over Year SHENYANG, China, February 25, 2010 For the year ended December 31, 2009, the Company anticipates it will record revenues in the range of $20 to $21 million, which represents an approximate increase of 28% when compared to $15.83 of]
NFEC [NF Energyvingrp] 8-K: (Original Filing)
[NF Energyvingrporation Issues Preliminary 2009 Results Thempany Expects 28% Revenue Growth and 250% EPS Growth Year over Year SHENYANG, China, February 25, 2010 For the year ended December 31, 2009, thempany anticipates it will record revenues in the range of $20 to $21 million, which represents an approximaterease of 28% whenmpared to $15.83 of revenues]
